Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

AIM

AIM ImmunoTech Inc

Apr 15 • 04:00PM ET

0.4848

Dollar change -0.0772
Percentage change -13.74	%

Healthcare • Biotechnology • USA • AMEX

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.59	Insider Own	9.18%	Shs Outstand	49.10M	Perf Week	-0.82%
Market Cap	24.19M	Forward P/E	-	EPS next Y	-0.47	Insider Trans	6.43%	Shs Float	45.32M	Perf Month	45.37%
Income	-28.96M	PEG	-	EPS next Q	-	Inst Own	8.32%	Short Float	1.09%	Perf Quarter	7.21%
Sales	0.20M	P/S	120.96	EPS this Y	10.00%	Inst Trans	-3.63%	Short Ratio	2.17	Perf Half Y	4.94%
Book/sh	0.19	P/B	2.49	EPS next Y	12.96%	ROA	-64.84%	Short Interest	0.49M	Perf Year	9.93%
Cash/sh	0.26	P/C	1.85	EPS next 5Y	25.00%	ROE	-118.94%	52W Range	0.32 - 0.75	Perf YTD	10.21%
Dividend Est.	-	P/FCF	-	EPS past 5Y	42.86%	ROI	-269.94%	52W High	-35.25%	Beta	-0.19
Dividend TTM	-	Quick Ratio	1.68	Sales past 5Y	-2.98%	Gross Margin	-62.38%	52W Low	51.45%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	1.68	EPS Y/Y TTM	-46.75%	Oper. Margin	-15793.56%	RSI (14)	51.97	Volatility	13.50% 12.65%
Employees	26	Debt/Eq	0.07	Sales Y/Y TTM	44.29%	Profit Margin	-14337.62%	Recom	1.00	Target Price	2.00
Option/Short	No / Yes	LT Debt/Eq	0.05	EPS Q/Q	-180.50%	Payout	-	Rel Volume	0.94	Prev Close	0.56
Sales Surprise	69.86%	EPS Surprise	-116.67%	Sales Q/Q	16.07%	Earnings	Apr 02 BMO	Avg Volume	226.74K	Price	0.48
SMA20	4.45%	SMA50	13.92%	SMA200	-3.63%	Trades		Volume	213,231	Change	-13.74%

Apr-15-24 08:55AM	AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs (GlobeNewswire) -13.74%
Apr-11-24 11:00AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +10.05%
Apr-10-24 08:21AM	AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer (GlobeNewswire) +12.96%
Apr-02-24 07:30AM	AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -8.18%
Mar-28-24 08:05AM	AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference (GlobeNewswire) +6.32%
09:05AM	Loading…
Mar-26-24 09:05AM	AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast (GlobeNewswire)
Mar-25-24 09:05AM	AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research (GlobeNewswire)
Mar-22-24 08:55AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +16.46%
Mar-20-24 09:25AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Mar-15-24 08:45AM	AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity (GlobeNewswire)
Mar-07-24 08:45AM	AIM ImmunoTech Announces Launch of CEO Corner Platform (GlobeNewswire)
Feb-29-24 08:45AM	AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update (GlobeNewswire)
Feb-14-24 08:55AM	AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZenecas Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire)
Feb-08-24 08:50AM	AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire) -12.64%
Jan-24-24 09:10AM	AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer (GlobeNewswire) -6.88%
08:55AM	Loading…
Jan-22-24 08:55AM	AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZenecas Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer (GlobeNewswire)
Jan-10-24 08:45AM	AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZenecas Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire)
Jan-05-24 01:32PM	AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting (Business Wire) -8.14%
Jan-03-24 04:05PM	Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied (PR Newswire)
Dec-29-23 08:00AM	Delaware Court Rules in Favor of AIM ImmunoTech and Upholds Boards Determination that Activist Groups Nominations Are Invalid (Business Wire) -8.73%
Nov-28-23 04:30PM	AIM ImmunoTech Provides Update Regarding Annual Meeting (Business Wire)
Nov-27-23 09:00PM	AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents (GlobeNewswire)
Nov-21-23 12:00PM	AIM ImmunoTech Completes Treatment of Last Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire)
Nov-16-23 08:45AM	Kellner Group Urges Stockholders of AIM Immunotech to Vote Gold Card Now for Desperately Needed Change (PR Newswire)
Nov-15-23 07:30AM	AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides Clinical Pipeline Update (GlobeNewswire)
Nov-14-23 10:00AM	AIM ImmunoTech Announces Publication of Data from Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen in Metastatic Triple-Negative Breast Cancer (GlobeNewswire)
Nov-09-23 08:05AM	AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast (GlobeNewswire) -8.12%
Nov-08-23 08:45AM	AIM ImmunoTech Announces Encouraging Translational Data from Phase 2 Study Evaluating Ampligen® for the Treatment of Advanced Recurrent Ovarian Cancer (GlobeNewswire)
Nov-06-23 09:25AM	AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders (Business Wire) -8.99%
Oct-30-23 08:55AM	AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) +6.98%
08:45AM	Loading…
Oct-17-23 08:45AM	AIM ImmunoTech Engages Business Development Firm, Azenova, LLC to Catalyze Partnering, Development and Commercialization Efforts for Ampligen® Pipeline Programs (GlobeNewswire) +10.43%
Sep-22-23 09:05AM	AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care (GlobeNewswire)
Sep-11-23 01:00PM	AIM ImmunoTech Announces Report of Complete Topline Data from Roswell Park Comprehensive Cancer Center Study Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer (GlobeNewswire) +7.97%
Sep-05-23 09:05AM	AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-23-23 08:00AM	AIM ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading Statements (Business Wire)
Aug-15-23 06:45AM	AIM ImmunoTech Reports Second Quarter Financial Results and Provides Clinical Pipeline Update (GlobeNewswire) -6.34%
Aug-09-23 09:05AM	AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast (GlobeNewswire)
Aug-08-23 08:05AM	AIM ImmunoTech Announces Completion of Enrollment in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire)
Jul-18-23 07:30PM	AIM ImmunoTech Issues Notice that an Unaffiliated Third Party and Organization are Providing False Information Related to Relationship with Company and its Affiliates (GlobeNewswire) +8.43%
06:53AM	Daily Vickers Top Buyers & Sellers for 07/18/2023 (Argus Research)
Jul-10-23 08:05AM	AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire)
Jul-05-23 08:35AM	AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series (GlobeNewswire)
Jun-27-23 11:16AM	AIM ImmunoTech Announces Publication of Positive Findings from a Pre-Clinical Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the American Journal of Cancer Research (GlobeNewswire) +7.02%
08:45AM	AIM ImmunoTech Announces Authorizations from Competent Authority and Ethics Board in the Netherlands to Begin a Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZenecas Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire)
Jun-14-23 08:45AM	AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire)
Jun-12-23 08:45AM	AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments (GlobeNewswire)
Jun-07-23 07:11PM	AIMIA ADOPTS SHAREHOLDER RIGHTS PLAN TO PROTECT AGAINST "CREEPING" BIDS AND UNEQUAL TREATMENT OF SHAREHOLDERS (PR Newswire)
May-15-23 08:45AM	AIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update (GlobeNewswire)
May-09-23 08:50AM	AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast (GlobeNewswire)
08:46AM	AIMIA ANNOUNCES CLOSING OF BOZZETTO TRANSACTION (PR Newswire)
Apr-20-23 03:56PM	AIMIA'S LARGEST SHAREHOLDER THANKS FELLOW SHAREHOLDERS FOR SUPPORTING CHANGE; MITHAQ EXPLORING ALL OPTIONS TO ENSURE VALIDITY OF RESULTS (PR Newswire)
Apr-12-23 08:35AM	AIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB) (GlobeNewswire) +9.15%
07:30AM	AIMIA'S LARGEST SHAREHOLDER REMINDS FELLOW SHAREHOLDERS TO VOTE AGAINST BOARD PRIOR TO PROXY VOTING DEADLINE (PR Newswire)
Apr-10-23 07:30AM	AIMIA'S LARGEST SHAREHOLDER ENCOURAGES FELLOW SHAREHOLDERS TO VOTE AGAINST BOARD (PR Newswire)
Apr-04-23 08:45AM	AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions (GlobeNewswire) +6.05%
Apr-03-23 06:30AM	AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-30-23 08:45AM	AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise (GlobeNewswire)
Mar-27-23 09:05AM	AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast (GlobeNewswire) -5.05%
Mar-16-23 08:45AM	AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease (GlobeNewswire) +5.00%
07:00AM	AIMIA REPORTS FOURTH QUARTER 2022 RESULTS (PR Newswire)
07:00AM	AIMIA DECLARES PREFERRED SHARE DIVIDENDS (PR Newswire)
Mar-08-23 08:45AM	AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease (GlobeNewswire)
Mar-06-23 08:45AM	AIM ImmunoTech Issues Letter to Stockholders (GlobeNewswire)
Feb-28-23 08:45AM	AIM ImmunoTech Announces Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer is Open and Recruiting Patients (GlobeNewswire) +8.37%
Feb-17-23 08:55AM	AIM ImmunoTech to Participate in Solve M.E. and The Biotechnology Innovation Organization (BIO) Virtual Event, Long Covid: What Will It Take To Accelerate Therapeutic Progress? (GlobeNewswire) +6.40%
Jan-17-23 08:45AM	AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center (GlobeNewswire) +22.53%
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE) +21.75%
Jan-09-23 08:05AM	AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention (GlobeNewswire)
Jan-05-23 08:45AM	AIM ImmunoTech to Present at the Virtual Investor 2023 Companies to Watch Event (GlobeNewswire) +13.54%
Dec-12-22 09:00AM	AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer (GlobeNewswire)
Dec-08-22 08:05AM	AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects (GlobeNewswire)
Dec-02-22 10:45AM	AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022 (GlobeNewswire)
Nov-15-22 07:00AM	AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-14-22 07:00AM	AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer (GlobeNewswire) -6.82%
Nov-09-22 09:00AM	AIM ImmunoTech Announces Corporate Governance Enhancements (Business Wire)
Nov-03-22 12:34PM	AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting (Business Wire)
Nov-02-22 07:05AM	AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease (GlobeNewswire)
Nov-01-22 05:19PM	Statement of the ASFV Committee on Ruling in Delaware Action (GlobeNewswire)
Oct-31-22 07:30AM	Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Groups Nominations Valid (Business Wire) +5.05%
Oct-26-22 05:12PM	AIM ImmunoTech Board Issues Letter to Shareholders (Business Wire)
Oct-24-22 08:30AM	ASFV Committee Reveals Troubling Statements Made by Entrenched AIM Board Uncovered Through Discovery in Delaware Action (GlobeNewswire)
Oct-13-22 10:32AM	U.S. District Court Dismisses AIMs "Baseless" Section 13(d) Claim (GlobeNewswire)
Oct-12-22 04:32PM	AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions (GlobeNewswire) -7.87%
Sep-21-22 08:45AM	AIM ImmunoTech to Present at the Virtual Investor Long COVID Event (GlobeNewswire)
Sep-19-22 08:05AM	AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders (Business Wire)
Sep-07-22 07:25AM	AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-06-22 07:30AM	AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care (GlobeNewswire)
Aug-30-22 07:30AM	AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma (GlobeNewswire)
Aug-18-22 09:05AM	AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer (GlobeNewswire)
Aug-16-22 04:05PM	AIM Stockholder Full Value Committee Reiterates Intent to Proceed with Nominations and Proxy Solicitation (GlobeNewswire) -5.50%
Aug-15-22 04:05PM	AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation (Business Wire)
08:05AM	AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-28-22 09:10AM	AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID (GlobeNewswire)
Jul-21-22 12:26PM	UPDATE -- AIM Stockholder Full Value Committee Announces Director Nominations for AIM Annual Meeting and Confirms Intent to Proceed with Proxy Solicitation (GlobeNewswire)
Jul-20-22 08:05AM	AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data (GlobeNewswire) +11.06%
Jul-18-22 08:00AM	AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid (GlobeNewswire)
Jul-14-22 08:05AM	AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series (GlobeNewswire)
Jun-21-22 08:35AM	AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing (GlobeNewswire)
Jun-13-22 08:05AM	AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention (GlobeNewswire) -6.82%
May-19-22 08:00AM	AIM ImmunoTech to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +5.44%

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BRYAN NANCY	Director	Mar 21 '24	Buy	0.39	38,462	15,000	38,462	Mar 22 01:30 PM
APPELROUTH STEWART	Director	Mar 15 '24	Buy	0.33	90,910	30,000	239,765	Mar 18 03:01 PM
Equels Thomas K	CEO & President	Mar 15 '24	Buy	0.33	75,758	25,000	716,455	Mar 18 03:01 PM
Rodino Peter W III	COO, Secretary, Gen. Counsel	Mar 15 '24	Buy	0.33	37,879	12,500	181,718	Mar 18 03:01 PM
Equels Thomas K	CEO & President	Nov 27 '23	Buy	0.44	33,861	15,000	640,697	Nov 27 12:56 PM
Equels Thomas K	CEO & President	Sep 29 '23	Buy	0.44	22,676	10,000	606,836	Sep 29 03:29 PM
Equels Thomas K	CEO & President	Aug 25 '23	Buy	0.67	8,222	5,501	584,160	Aug 25 02:26 PM
Equels Thomas K	CEO & President	Aug 24 '23	Buy	0.67	14,993	10,000	575,938	Aug 24 01:52 PM
Equels Thomas K	CEO & President	Jul 17 '23	Buy	0.59	16,950	10,000	560,945	Jul 17 07:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIM

AIM ImmunoTech Inc

Upgrade your FINVIZ experience